Health Care & Life Sciences » Biotechnology | BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. | Income Statement

Fiscal year is August-July. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
79.90
61.20
0.60
1.80
0.30
16.90
Gross Income
79.90
61.20
0.60
1.80
0.30
16.90
SG&A Expense
368.40
414.80
1,873.40
2,175.40
3,217.90
4,959.60
EBIT
288.50
476.00
1,873.90
2,177.20
3,218.20
4,976.50
Unusual Expense
100.00
8,345.60
1,674.50
27.80
-
407.70
Non Operating Income/Expense
8.80
78.40
50.40
14.60
8.90
24.10
Pretax Income
379.90
8,886.90
3,488.80
2,214.80
3,220.70
5,412.70
Consolidated Net Income
379.90
8,886.90
3,488.80
2,214.80
3,220.70
5,412.70
Net Income
379.90
8,886.90
3,488.80
2,214.80
3,220.70
5,412.70
Net Income After Extraordinaries
379.90
8,886.90
3,488.80
2,214.80
3,220.70
5,412.70
Net Income Available to Common
379.90
8,886.90
3,488.80
2,214.80
3,220.70
5,412.70
EPS (Basic)
0.03
0.49
0.05
0.03
0.03
0.04
Basic Shares Outstanding
17,702.70
17,702.70
74,261.00
86,541.70
101,912.20
128,344.40
EPS (Diluted)
0.02
0.50
0.05
0.03
0.03
0.04
Diluted Shares Outstanding
17,702.70
17,702.70
74,261.00
86,541.70
101,912.20
128,344.40
EBITDA
288.10
474.80
1,873.40
2,175.40
3,218.00
4,959.60
Non-Operating Interest Income
17.40
13.10
9.20
4.70
6.40
16

About BriaCell Therapeutics

View Profile
Address
Bellevue Centre
West Vancouver British Columbia V7T 2X1
Canada
Employees -
Website http://www.briacell.com
Updated 07/08/2019
BriaCell Therapeutics Corp. operates as an immuno-oncology company which engages in the development of immunotherapy treatments for cancer. Its product candidate, BriaVax, is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. It is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.